Pharscin Pharma(SZ:002907) Xin Lang Cai Jing·2025-08-22 02:14Core Insights - Huason Pharmaceutical (002907.SZ) reported a total operating revenue of 442 million yuan for the first half of 2025, an increase of 24.06 million yuan compared to the same period last year, marking a year-on-year growth of 5.76% [1] - The net profit attributable to shareholders reached 53.95 million yuan, up by 6.74 million yuan from the previous year, reflecting a year-on-year increase of 14.27% [1] - The company achieved a net cash inflow from operating activities of 27.53 million yuan [1] Financial Metrics - The latest debt-to-asset ratio stands at 15.43% [3] - The gross profit margin is 58.74%, which is an increase of 0.85 percentage points from the same period last year [3] - Return on equity (ROE) is reported at 3.20%, up by 0.33 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.13 yuan, an increase of 0.02 yuan compared to the same period last year, representing a year-on-year growth of 14.24% [3] - The total asset turnover ratio is 0.22 times, remaining stable compared to the previous year [3] - The inventory turnover ratio is 1.40 times, an increase of 0.17 times year-on-year, reflecting a growth of 14.09% [3] Shareholder Structure - The number of shareholders is reported at 32,800, with the top ten shareholders holding a total of 326 million shares, accounting for 78.09% of the total share capital [3] - The largest shareholder is Chengdu Local Construction Machinery Engineering Co., Ltd., holding 40.49% of the shares [3] - Other significant shareholders include You Hongtao (17.34%), Wang Ying (8.76%), and Liu Xiaoying (8.60%) [3]